November 07, 2016
Survey Sheds Light on Under-Recognized Digestive Condition, EPI

In the U.S. alone, approximately 60 to 70 million people1 are affected by digestive conditions, most of which are chronic in nature. Unfortunately, many in this group struggle with pinpointing the disease itself and how to treat it.

To help explore perceptions of gastrointestinal (GI) health in the U.S., AbbVie recently launched the results of EPI Uncovered – a survey commissioned with the American Gastroenterological Association (AGA) to explore the understanding of the role of the pancreas in digestive health. The survey also uncovers the barriers to diagnosis of exocrine pancreatic insufficiency (EPI), an under-recognized digestive condition caused by a deficiency in pancreatic enzyme-production and characterized by ongoing GI symptoms.

The survey is the largest U.S. analysis of GI patients, gastroenterologists and primary care physicians that looks to uncover information about digestive health. Key findings include:


Additional survey results are available on and for more information about EPI, visit



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?